TN2019000143A1 - Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders - Google Patents
Substituted pyrido[3,4-b]indoles for the treatment of cartilage disordersInfo
- Publication number
- TN2019000143A1 TN2019000143A1 TNP/2019/000143A TN2019000143A TN2019000143A1 TN 2019000143 A1 TN2019000143 A1 TN 2019000143A1 TN 2019000143 A TN2019000143 A TN 2019000143A TN 2019000143 A1 TN2019000143 A1 TN 2019000143A1
- Authority
- TN
- Tunisia
- Prior art keywords
- sup
- indoles
- treatment
- cartilage
- substituted
- Prior art date
Links
- 208000015100 cartilage disease Diseases 0.000 title abstract 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 title 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 230000022159 cartilage development Effects 0.000 abstract 1
- 230000008421 cartilage matrix synthesis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002475 indoles Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9Hpyrid[ 3,4-b ]indoles of the formula (I), in which A, E, G, R<sup>1</sup> to R<sup>6</sup> and R<sup>10</sup> are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (1), their use as pharmaceuticals, and pharmaceutical compositions comprising them.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306452.0A EP3318563A1 (en) | 2016-11-07 | 2016-11-07 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| PCT/EP2017/078026 WO2018083157A1 (en) | 2016-11-07 | 2017-11-02 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2019000143A1 true TN2019000143A1 (en) | 2020-10-05 |
Family
ID=57286428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP/2019/000143A TN2019000143A1 (en) | 2016-11-07 | 2017-11-02 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11130755B2 (en) |
| EP (3) | EP3318563A1 (en) |
| JP (1) | JP7046063B2 (en) |
| KR (1) | KR102490199B1 (en) |
| CN (1) | CN110382496B (en) |
| AR (1) | AR110136A1 (en) |
| AU (2) | AU2017353381B2 (en) |
| CA (1) | CA3042332A1 (en) |
| CL (1) | CL2019001251A1 (en) |
| CO (1) | CO2019005090A2 (en) |
| CR (1) | CR20190217A (en) |
| DK (1) | DK3535263T3 (en) |
| DO (1) | DOP2019000112A (en) |
| EA (1) | EA038365B1 (en) |
| EC (1) | ECSP19031458A (en) |
| ES (1) | ES2837765T3 (en) |
| HR (1) | HRP20201754T1 (en) |
| HU (1) | HUE052187T2 (en) |
| IL (1) | IL265982B (en) |
| LT (1) | LT3535263T (en) |
| MA (1) | MA45803B1 (en) |
| MX (1) | MX383580B (en) |
| MY (1) | MY189589A (en) |
| PE (1) | PE20191032A1 (en) |
| PH (1) | PH12019500997B1 (en) |
| PT (1) | PT3535263T (en) |
| RS (1) | RS61172B1 (en) |
| SG (1) | SG11201903195YA (en) |
| SI (1) | SI3535263T1 (en) |
| TN (1) | TN2019000143A1 (en) |
| TW (1) | TWI753966B (en) |
| UY (1) | UY37473A (en) |
| WO (1) | WO2018083157A1 (en) |
| ZA (1) | ZA201902111B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
| CN111936490A (en) | 2017-11-20 | 2020-11-13 | 西奈山伊坎医学院 | Kinase inhibitor compounds and compositions and methods of use |
| US11788064B2 (en) | 2018-01-05 | 2023-10-17 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| EP3768267B1 (en) * | 2018-03-20 | 2025-05-14 | Icahn School of Medicine at Mount Sinai | Beta-carboline derivatives as dyrk1a inhibitors for the treatment of e.g. diabetes |
| US11485734B2 (en) | 2018-10-02 | 2022-11-01 | Northwestern University | Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C) |
| KR20220044721A (en) * | 2019-08-06 | 2022-04-11 | 도메인 테라퓨틱스 | 5-Heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists |
| CN114763347B (en) * | 2021-01-15 | 2024-06-21 | 华东师范大学 | A class of compounds for inducing mesenchymal stem cells to differentiate into cartilage and their application |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194747A (en) * | 1979-08-29 | 1988-11-29 | Schering Ag | 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives |
| US4631149A (en) | 1983-07-25 | 1986-12-23 | University Of Illinois | Antiviral eudistomins from a marine tunicate |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| ECSP951529A (en) | 1995-09-05 | 1997-05-16 | PHARMACEUTICAL COMPOUNDS | |
| EP1134221A1 (en) * | 2000-03-15 | 2001-09-19 | Aventis Pharma Deutschland GmbH | Substituted beta-carbolines as lkB kinase inhibitors |
| EP1268477B1 (en) | 2000-03-15 | 2010-04-21 | Sanofi-Aventis Deutschland GmbH | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| JP4599501B2 (en) | 2001-11-07 | 2010-12-15 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Carboline derivatives as inhibitors of Ikappa B in the treatment of multiple myeloma and other cancers - Patents.com |
| FR2838123B1 (en) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | NOVEL SUBSTITUTED INDOLOZIN-1,2,3 DERIVATIVES, SELECTIVE B-FGF INHIBITORS |
| WO2006013739A1 (en) | 2004-08-04 | 2006-02-09 | Konica Minolta Holdings, Inc. | Organic electroluminescent device, illuminating device and display |
| CA2658511C (en) | 2006-08-25 | 2019-02-19 | Ares Trading S.A. | Use of fgf-18 compound to treat cartilage disorders |
| WO2008132454A1 (en) | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| FR2916380B1 (en) * | 2007-05-21 | 2009-07-31 | Saint Gobain | METHOD AND DEVICE FOR OVERMOULTING A GLASS ELEMENT BY A SEAL PORTION COMPRISING AN INSERT, GLAZING AND INSERT IN PARTICULAR FOR THIS METHOD. |
| WO2010038153A1 (en) | 2008-10-01 | 2010-04-08 | The University Of British Columbia | Use of sox transcription factor acti\ators for stimulating chondrogenesis |
| US9962368B2 (en) * | 2009-01-09 | 2018-05-08 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| EP2455378A1 (en) * | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| JP5854492B2 (en) | 2011-02-24 | 2016-02-09 | 国立大学法人 岡山大学 | Chondrocyte differentiation inducer |
| UY35809A (en) | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (AZA) PIRIDOPIRAZOLOPIRIMIDINONAS AND INDAZOLOPIRIMIDINONAS AND ITS USES |
| JP2015107945A (en) | 2013-12-05 | 2015-06-11 | 国立大学法人京都大学 | Neurogenesis compounds and pharmaceutical compositions |
| EP3318563A1 (en) | 2016-11-07 | 2018-05-09 | Sanofi | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders |
-
2016
- 2016-11-07 EP EP16306452.0A patent/EP3318563A1/en not_active Withdrawn
-
2017
- 2017-11-02 HR HRP20201754TT patent/HRP20201754T1/en unknown
- 2017-11-02 SI SI201730476T patent/SI3535263T1/en unknown
- 2017-11-02 AU AU2017353381A patent/AU2017353381B2/en active Active
- 2017-11-02 ES ES17794307T patent/ES2837765T3/en active Active
- 2017-11-02 PT PT177943073T patent/PT3535263T/en unknown
- 2017-11-02 WO PCT/EP2017/078026 patent/WO2018083157A1/en not_active Ceased
- 2017-11-02 PE PE2019000879A patent/PE20191032A1/en unknown
- 2017-11-02 SG SG11201903195YA patent/SG11201903195YA/en unknown
- 2017-11-02 CA CA3042332A patent/CA3042332A1/en active Pending
- 2017-11-02 EP EP20198613.0A patent/EP3792262A1/en active Pending
- 2017-11-02 PH PH1/2019/500997A patent/PH12019500997B1/en unknown
- 2017-11-02 KR KR1020197016225A patent/KR102490199B1/en active Active
- 2017-11-02 CN CN201780081846.4A patent/CN110382496B/en active Active
- 2017-11-02 RS RS20201512A patent/RS61172B1/en unknown
- 2017-11-02 HU HUE17794307A patent/HUE052187T2/en unknown
- 2017-11-02 EA EA201991144A patent/EA038365B1/en unknown
- 2017-11-02 CR CR20190217A patent/CR20190217A/en unknown
- 2017-11-02 MA MA45803A patent/MA45803B1/en unknown
- 2017-11-02 DK DK17794307.3T patent/DK3535263T3/en active
- 2017-11-02 EP EP17794307.3A patent/EP3535263B1/en active Active
- 2017-11-02 MX MX2019005308A patent/MX383580B/en unknown
- 2017-11-02 US US16/347,386 patent/US11130755B2/en active Active
- 2017-11-02 MY MYPI2019001925A patent/MY189589A/en unknown
- 2017-11-02 LT LTEP17794307.3T patent/LT3535263T/en unknown
- 2017-11-02 TN TNP/2019/000143A patent/TN2019000143A1/en unknown
- 2017-11-02 JP JP2019522912A patent/JP7046063B2/en active Active
- 2017-11-03 TW TW106138038A patent/TWI753966B/en active
- 2017-11-07 UY UY0001037473A patent/UY37473A/en not_active Application Discontinuation
- 2017-11-07 AR ARP170103083A patent/AR110136A1/en active IP Right Grant
-
2019
- 2019-04-04 ZA ZA2019/02111A patent/ZA201902111B/en unknown
- 2019-04-11 IL IL265982A patent/IL265982B/en active IP Right Grant
- 2019-05-02 DO DO2019000112A patent/DOP2019000112A/en unknown
- 2019-05-06 EC ECSENADI201931458A patent/ECSP19031458A/en unknown
- 2019-05-07 CL CL2019001251A patent/CL2019001251A1/en unknown
- 2019-05-17 CO CONC2019/0005090A patent/CO2019005090A2/en unknown
-
2021
- 2021-08-23 US US17/409,513 patent/US11827633B2/en active Active
- 2021-08-24 AU AU2021221468A patent/AU2021221468B2/en active Active
-
2023
- 2023-10-17 US US18/488,871 patent/US12275733B2/en active Active
-
2025
- 2025-03-03 US US19/068,406 patent/US20250333412A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2019000143A1 (en) | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | |
| EP4527461A3 (en) | A compound, compositions thereof and this compound for use in methods of treating cns disorders | |
| MX378717B (en) | HETEROCYLIC CARBOXYLIC ACIDS AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS. | |
| MX387443B (en) | HETEROARYLCARBOXAMIDE COMPOUNDS AS RIPK2 INHIBITORS | |
| MX375925B (en) | IMIDAZO[1,2-A]PYRAZIN-1-YL-BENZAMIDE COMPOUNDS FOR TREATMENT OF SPINAL MUSCULAR ATROPHY. | |
| MX2019014292A (en) | 5-5 FUSED RINGS AS C5a INHIBITORS. | |
| TN2017000485A1 (en) | Tricyclic compounds and their use as phosphodiesterase inhibitors | |
| PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| WO2017177004A8 (en) | Tertiary amides and method of use | |
| PH12017500089B1 (en) | Aldosterone synthase inhibitors | |
| MX2020001531A (en) | NEW HETOROCYCLIC COMPOUNDS AS INHIBITORS OF CDK8/19. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX379327B (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| MX379704B (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds | |
| CY1120744T1 (en) | AZAINDOLIS ACETIC ACID PRODUCERS AND THE USE OF THESE AS REGULATORY PROSTAGLANDIN RECEPTORS D2 | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| MX2019014272A (en) | Ergoline derivatives for use in medicine. | |
| PH12013501938A1 (en) | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators | |
| MX2016011900A (en) | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators. | |
| EA201790795A1 (en) | COMPOUNDS 4H-PYRIDO [1,2-a] PYRIMIDIN-4-IT |